Cargando…

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors

Aim: We evaluated MK-8353 (small molecule inhibitor of extracellular signal-regulated kinase 1/2) plus selumetinib (mitogen-activated extracellular signal-regulated kinase 1/2 inhibitor) in patients with advanced solid tumors. Methods: This phase 1b, open-label, dose-escalation study (NCT03745989) e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stathis, Anastasios, Tolcher, Anthony W., Wang, Judy S., Renouf, Daniel J., Chen, Lin-Chi, Suttner, Leah H., Freshwater, Tomoko, Webber, Andrea L., Nayak, Tapan, Siu, Lillian L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289957/ https://www.ncbi.nlm.nih.gov/pubmed/37040046 http://dx.doi.org/10.1007/s10637-022-01326-3

Ejemplares similares

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
por: Nakai, Chikako, et al.
Publicado: (2023)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
por: Dymond, Angela W., et al.
Publicado: (2017)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
por: Haslett, K., et al.
Publicado: (2021)

The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo
por: Zou, Yun, et al.
Publicado: (2017)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors
por: Desar, Ingrid M. E., et al.
Publicado: (2012)

Could HBx Protein Expression Affect Signal Pathway Inhibition by Gefitinib or Selumetinib, a MEK Inhibitor, in Hepatocellular Carcinoma Cell Lines?
por: Park, Yoon Kyung, et al.
Publicado: (2011)

A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib
por: Takekuma, Munetaka, et al.
Publicado: (2016)

Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib
por: Novo, Sonia M., et al.
Publicado: (2017)

Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
por: Zheng, Xiaohang, et al.
Publicado: (2022)

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
por: Beloueche-Babari, M, et al.
Publicado: (2013)

The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia
por: Au, Ernie D., et al.
Publicado: (2017)

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
por: Davis, Thomas B., et al.
Publicado: (2019)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
por: Molife, L Rhoda, et al.
Publicado: (2014)

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
por: Troiani, T, et al.
Publicado: (2012)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
por: Farnsworth, Dylan A., et al.
Publicado: (2022)

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma
por: Gaudio, Eugenio, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
por: Dymond, Angela W., et al.
Publicado: (2016)

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
por: Wilky, B A, et al.
Publicado: (2015)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis
por: Cheng, Zhe, et al.
Publicado: (2020)

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway
por: Wang, Zhenlin, et al.
Publicado: (2019)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway
por: Li, Chen, et al.
Publicado: (2016)

Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors
por: Lieske, Nora V., et al.
Publicado: (2015)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022)

Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2
por: Gurgis, FMS, et al.
Publicado: (2015)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
por: Iezzi, Alice, et al.
Publicado: (2018)

Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma
por: Zheng, Zhen-Yuan, et al.
Publicado: (2022)

First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
por: Siu, Lillian L., et al.
Publicado: (2022)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
por: Leijen, Suzanne, et al.
Publicado: (2011)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

Effect of food on capsule and granule formulations of selumetinib
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f0pa4aui8vdlg3kegoo476cif2